Kaposi's sarcoma in pregnancy: Two case reports

Taylor, J.; Templeton, A. C.; Kylwazi, S; Lubega, Abubaker

doi:10.1002/bjs.1800580808

Cited by 19 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All 12 patients had the mixed cell type histological picture which is consistent with an earlier report where lymphadenopathic disease was also exclusively of mixed cellular type (Taylor et al, 1971b). This histological appearance occurs overall in some 70% of adult Kaposi sarcoma patients in Uganda (Olweny et al, 1974).…”

Section: Resultssupporting

confidence: 87%

“…So far there is no satisfactory explanation for the sex distribution. Sex hormones have been suggested as possibly protecting the post-pubertal females, but treatment with oestrogens has yielded no beneficial results, and some patients have developed the disease while pregnant (Taylor et al, 1971b). However, review of childhood cases in Uganda prior to 1967 revealed that all 9 recorded cases were males (Davies and Lothe, 1962).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Childhood Kaposi's sarcoma: Clinical features and therapy

Olweny¹,

Kaddumukasa²,

Atine³

et al. 1976

Br J Cancer

View full text Add to dashboard Cite

Twelve cases of childhood Kaposi's sarcoma seen at the Uganda Cancer Institute over the last 7 years are reported. The disease presents mainly as generalized lymphadenopathy, with sparsely and anomalously distributed cutaneous nodules, and has a higher proportion of females with the disease than in the adult form. The histology is usually of mixed cell type. If not treated, childhood Kaposi's sarcoma runs a fulminating course, but disease control with chemotherapy is associated with prolonged survival. Images Fig. 1 Fig. 2 Fig. 3 Fig. 4

show abstract

Section: Resultssupporting

confidence: 87%

Section: Resultsmentioning

confidence: 99%

Childhood Kaposi's sarcoma: Clinical features and therapy

Olweny¹,

Kaddumukasa²,

Atine³

et al. 1976

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Second, the cell growth inhibitory effects thought to be associated with hCG are entirely contrary to its ability to suppress apoptotic cell death in reproductive organs [8]. Third, although some data suggest that preg- nancy might protect against KS [4,5], the effect of pregnancy and pregnancy-related factors on KS is not clear since descriptions of KS development or progression during pregnancy have also been reported [9][10][11]. A single retrospective study by Rabkin et al [12] in HIV-1-infected African women found that pregnancy was not associated with lower KS rates.…”

Section: How Serendipitous Findings Led To the Investigation Of Hcg Amentioning

confidence: 86%

Treatment of Kaposi’s Sarcoma with Human Chorionic Gonadotropin

Simonart¹,

Vooren

Meuris³

2002

Dermatology

View full text Add to dashboard Cite

Clinical-grade preparations of human chorionic gonadotropin (hCG) have been shown to be toxic to Kaposi’s sarcoma (KS) cells. However, the mechanism of the anti-KS activity achieved with these preparations remains unclear. The results of clinical studies using commercial hCG preparations in human KS are also highly contradictory. The apparent controversy between different studies may be due to the fact that pro- and anti-KS components are present in varying proportions in different hCG preparations. As certain hCG preparations could not only lack the ability to control KS but also contain some contaminant KS growth factor(s), we suggest a cautious use of crude hCG for the treatment of KS.

show abstract

“…Moreover, there are no reports to suggest this from KS in women, including pregnant women 23 , and in large cohorts in Uganda 34 and Zambia 13 . It is curious that although the incidence of AIDS-related KS in children, including those with vertically acquired HIV infection, is reportedly increasing 35 , apparently vertically transmitted KS is very rare.…”

Section: Evidence For Sexually Transmissible Aetiologymentioning

confidence: 93%

“…Hormonal in¯uence was initially thought to be responsible for lower incidence among women 8,21 , and seems to be supported by recent experimental data 22 . However, reports of KS during pregnancy 23 , low incidence among post-menopausal women 8 , and apparent absence of sex hormone receptors on KS tissue 24 confounds the role, if any, of sex hormones in the gender differences in incidence. Childhood KS also had inexplicable clinical presentation.…”

Section: Kaposi's Sarcoma In Africa Before Aidsmentioning

confidence: 96%

Sexually transmissible agent and African Kaposi's sarcoma

Matondo¹,

Sivapalan²

1996

Int J STD AIDS

View full text Add to dashboard Cite

Kaposi's sarcoma (KS) has a higher incidence in some parts of Africa than anywhere else in the world. Recent studies in western homosexual men with AIDS-KS suggest that KS may be caused by a putative sexually transmissible agent. Our analytical review of studies on KS in Africa before and during the AIDS era reveals a disparate epidemiological picture. Its occurrence in sexually inexperienced children; overwhelming male preponderance in an almost exclusively heterosexual population; rarity of concordant couples in areas of very high incidence; sequestration of high incidence to Eastern and Central Africa; and regional variations in incidence even in high-incidence countries are all difficult to reconcile with a conventional sexually transmissible aetiology. There is a need for prospective studies specifically designed to test the hypothesis in Africa. Also, we recommend that studies pursuing the aetiology of KS in western countries be linked with studies in high incidence areas in Africa.

show abstract

Kaposi's sarcoma in pregnancy: Two case reports

Cited by 19 publications

References 6 publications

Childhood Kaposi's sarcoma: Clinical features and therapy

Childhood Kaposi's sarcoma: Clinical features and therapy

Treatment of Kaposi’s Sarcoma with Human Chorionic Gonadotropin

Sexually transmissible agent and African Kaposi's sarcoma

Contact Info

Product

Resources

About